Risk Stratification and Treatment in Smoldering Multiple Myeloma

被引：6

作者：

Lussier, Tyler ^{[1
,2
]}

Schoebe, Natalie ^{[1
,3
,4
]}

Mai, Sabine ^{[1
]}

机构：

[1] Univ Manitoba, Canc Care Manitoba Res Inst, Dept Physiol & Pathophysiol, Winnipeg, MB R3E 0V9, Canada

[2] Univ St Boniface, Fac Sci, Winnipeg, MB R2H 0H7, Canada

[3] Heidelberg Univ, Fac Biosci, D-69117 Heidelberg, Germany

[4] Univ Cambridge, Dept Med Genet, Cambridge CB2 1TN, England

来源：

CELLS | 2022年 / 11卷 / 01期

基金：

加拿大健康研究院;

关键词：

smoldering multiple myeloma; risk stratification; treatment; LENALIDOMIDE PLUS DEXAMETHASONE; MONOCLONAL GAMMOPATHIES; UNDETERMINED SIGNIFICANCE; PROGRESSION; CRITERIA; GENES; ABNORMALITIES; INTERLEUKIN-6; PREDICT; LESIONS;

D O I：

10.3390/cells11010130

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Smoldering multiple myeloma is a heterogeneous asymptomatic precursor to multiple myeloma. Since its identification in 1980, risk stratification models have been developed using two main stratification methods: clinical measurement-based and genetics-based. Clinical measurement models can be subdivided in three types: baseline measurements (performed at diagnosis), evolving measurements (performed over time during follow-up appointments), and imaging (for example, magnetic resonance imaging). Genetic approaches include gene expression profiling, DNA/RNA sequencing, and cytogenetics. It is important to accurately distinguish patients with indolent disease from those with aggressive disease, as clinical trials have shown that patients designated as "high-risk of progression" have improved outcomes when treated early. The risk stratification models, and clinical trials are discussed in this review.

引用

页数：23

共 62 条

[1] Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma [J].

Aljama, Mohammed A. ;

Sidiqi, M. Hasib ;

Lakshman, Arjun ;

Dispenzieri, Angela ;

Jevremovic, Dragan ;

Gertz, Morie A. ;

Lacy, Martha Q. ;

Buadi, Francis K. ;

Dingli, David ;

Muchtar, Eli ;

Fonder, Amie L. ;

Hayman, Suzanne R. ;

Hobbs, Miriam A. ;

Gonsalves, Wilson, I ;

Warsame, Rahma ;

Kourelis, Taxiarchis, V ;

Hwa, Yi Lisa ;

Kapoor, Prashant ;

Leung, Nelson ;

Go, Ronald S. ;

Kyle, Robert A. ;

Rajkumar, S. Vincent ;

Kumar, Shaji K. .

BLOOD ADVANCES, 2018, 2 (22) :3149-3154

[2] Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma [J].

Atrash, Shebli ;

Robinson, Myra ;

Slaughter, Daniel ;

Aneralla, Amanda ;

Brown, Taylor ;

Robinson, Jordan ;

Ndiaye, Ami ;

Sprouse, Chelsea ;

Zhang, Qing ;

Symanowski, James T. ;

Friend, Reed ;

Voorhees, Peter M. ;

Usmani, Saad Z. ;

Bhutani, Manisha .

BLOOD CANCER JOURNAL, 2018, 8

[3] High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma [J].

Bianchi, G. ;

Kyle, R. A. ;

Larson, D. R. ;

Witzig, T. E. ;

Kumar, S. ;

Dispenzieri, A. ;

Morice, W. G. ;

Rajkumar, S. V. .

LEUKEMIA, 2013, 27 (03) :680-685

[4] Genomic patterns of progression in smoldering multiple myeloma [J].

Bolli, Niccolo ;

Maura, Francesco ;

Minvielle, Stephane ;

Gloznik, Dominik ;

Szalat, Raphael ;

Fullam, Anthony ;

Martincorena, Inigo ;

Dawson, Kevin J. ;

Samur, Mehmet Kemal ;

Zamora, Jorge ;

Tarpey, Patrick ;

Davies, Helen ;

Fulciniti, Mariateresa ;

Shammas, Masood A. ;

Tai, Yu Tzu ;

Magrangeas, Florence ;

Moreau, Philippe ;

Corradini, Paolo ;

Anderson, Kenneth ;

Alexandrov, Ludmil ;

Wedge, David C. ;

Avet-Loiseau, Herve ;

Campbell, Peter ;

Munshi, Nikhil .

NATURE COMMUNICATIONS, 2018, 9

[5] Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression [J].

Bustoros, Mark ;

Sklavenitis-Pistofidis, Romanos ;

Park, Jihye ;

Redd, Robert ;

Zhitomirsky, Benny ;

Dunford, Andrew J. ;

Salem, Karma ;

Tai, Yu-Tzu ;

Anand, Shankara ;

Mouhieddine, Tarek H. ;

Chavda, Selina J. ;

Boehner, Cody ;

Elagina, Liudmila ;

Neuse, Carl Jannes ;

Cha, Justin ;

Rahmat, Mahshid ;

Taylor-Weiner, Amaro ;

Van Allen, Eliezer ;

Kumar, Shaji ;

Kastritis, Efstathis ;

Leshchiner, Ignaty ;

Morgan, Elizabeth A. ;

Laubach, Jacob ;

Casneuf, Tineke ;

Richardson, Paul ;

Munshi, Nikhil C. ;

Anderson, Kenneth C. ;

Trippa, Lorenzo ;

Aguet, Francois ;

Stewart, Chip ;

Dimopoulos, Meletios-Athanasios ;

Yong, Kwee ;

Bergsagel, P. Leif ;

Manier, Salomon ;

Getz, Gad ;

Ghobrial, Irene M. .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (21) :2380-+

[6] Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma [J].

Cesana, C ;

Klersy, C ;

Barbarano, L ;

Nosari, AM ;

Crugnola, M ;

Pungolino, E ;

Gargantini, L ;

Granata, S ;

Valentini, M ;

Morra, E .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) :1625-1634

[7] Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types [J].

Chen, Zhishan ;

Wen, Wanqing ;

Bao, Jiandong ;

Kuhs, Krystle L. ;

Cai, Qiuyin ;

Long, Jirong ;

Shu, Xiao-ou ;

Zheng, Wei ;

Guo, Xingyi .

BMC MEDICAL GENOMICS, 2019, 12 (01)

[8] Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study [J].

Cherry, Benjamin M. ;

Korde, Neha ;

Kwok, Mary ;

Manasanch, Elisabet E. ;

Bhutani, Manisha ;

Mulquin, Marcia ;

Zuchlinski, Diamond ;

Yancey, Mary Ann ;

Maric, Irina ;

Calvo, Katherine R. ;

Braylan, Raul ;

Stetler-Stevenson, Maryalice ;

Yuan, Constance ;

Tembhare, Prashant ;

Zingone, Adriana ;

Costello, Rene ;

Roschewski, Mark J. ;

Landgren, Ola .

LEUKEMIA & LYMPHOMA, 2013, 54 (10) :2215-2218

[9] Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120) [J].

Dhodapkar, Madhav V. ;

Sexton, Rachael ;

Waheed, Sarah ;

Usmani, Saad ;

Papanikolaou, Xenofon ;

Nair, Bijay ;

Petty, Nathan ;

Shaughnessy, John D., Jr. ;

Hoering, Antje ;

Crowley, John ;

Orlowski, Robert Z. ;

Barlogie, Bart .

BLOOD, 2014, 123 (01) :78-85

[10] Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma [J].

Dispenzieri, Angela ;

Kyle, Robert A. ;

Katzmann, Jerry A. ;

Therneau, Terry M. ;

Larson, Dirk ;

Benson, Joanne ;

Clark, Raynell J. ;

Melton, L. Joseph, III ;

Gertz, Morie A. ;

Kumar, Shaji K. ;

Fonseca, Rafael ;

Jelinek, Diane F. ;

Rajkumar, S. Vincent .

BLOOD, 2008, 111 (02) :785-789

← 1 2 3 4 5 6 7 →